Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Fuji
Express Scripts
Merck
Cipla
Johnson and Johnson
McKinsey
McKesson
QuintilesIMS
US Department of Justice
Teva

Generated: October 20, 2017

DrugPatentWatch Database Preview

Pharmacyclics Inc Company Profile

« Back to Dashboard

What is the competitive landscape for PHARMACYCLICS INC, and when can generic versions of PHARMACYCLICS INC drugs launch?

PHARMACYCLICS INC has one approved drug.

There are eighteen US patents protecting PHARMACYCLICS INC drugs.

There are one hundred and seventy-two patent family members on PHARMACYCLICS INC drugs in thirty-eight countries and twenty-two supplementary protection certificates in ten countries.

Summary for Applicant: Pharmacyclics Inc

International Patents:172
US Patents:18
Tradenames:1
Ingredients:1
NDAs:1
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Pharmacyclics Inc
IMBRUVICA
ibrutinib
CAPSULE;ORAL205552-001Nov 13, 2013RXYesYes► Subscribe► Subscribe► Subscribe
Pharmacyclics Inc
IMBRUVICA
ibrutinib
CAPSULE;ORAL205552-001Nov 13, 2013RXYesYes► Subscribe► Subscribe ► Subscribe
Pharmacyclics Inc
IMBRUVICA
ibrutinib
CAPSULE;ORAL205552-001Nov 13, 2013RXYesYes► Subscribe► Subscribe► Subscribe
Pharmacyclics Inc
IMBRUVICA
ibrutinib
CAPSULE;ORAL205552-001Nov 13, 2013RXYesYes► Subscribe► Subscribe► Subscribe
Pharmacyclics Inc
IMBRUVICA
ibrutinib
CAPSULE;ORAL205552-001Nov 13, 2013RXYesYes► Subscribe► Subscribe ► Subscribe
Pharmacyclics Inc
IMBRUVICA
ibrutinib
CAPSULE;ORAL205552-001Nov 13, 2013RXYesYes► Subscribe► Subscribe ► Subscribe
Pharmacyclics Inc
IMBRUVICA
ibrutinib
CAPSULE;ORAL205552-001Nov 13, 2013RXYesYes► Subscribe► SubscribeYY ► Subscribe
Pharmacyclics Inc
IMBRUVICA
ibrutinib
CAPSULE;ORAL205552-001Nov 13, 2013RXYesYes► Subscribe► Subscribe► Subscribe
Pharmacyclics Inc
IMBRUVICA
ibrutinib
CAPSULE;ORAL205552-001Nov 13, 2013RXYesYes► Subscribe► SubscribeYY ► Subscribe
Pharmacyclics Inc
IMBRUVICA
ibrutinib
CAPSULE;ORAL205552-001Nov 13, 2013RXYesYes► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Pharmacyclics Inc

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,139,591Inhibitors of bruton's tyrosine kinase► Subscribe
8,158,786Inhibitors of Bruton's tyrosine kinase► Subscribe
9,206,189Inhibitors of bruton's tyrosine kinase► Subscribe
8,748,439Inhibitors of Bruton's tyrosine kinase► Subscribe
8,741,908Inhibitors of bruton's tyrosine kinase► Subscribe
8,691,546Inhibitors of Bruton's tyrosine kinase► Subscribe
8,809,273Inhibitors of Bruton's tyrosine kinase► Subscribe
7,732,454Inhibitors of Bruton's tyrosine kinase► Subscribe
8,399,470Inhibitors of bruton's tyrosine kinase► Subscribe
9,079,908Inhibitors of Bruton'S tyrosine kinase► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Pharmacyclics Inc Drugs

Country Document Number Estimated Expiration
South Korea101464424► Subscribe
BrazilPI0810086► Subscribe
South Korea20150015021► Subscribe
Israel239155► Subscribe
Japan5193256► Subscribe
Uruguay34848► Subscribe
Mexico347525► Subscribe
Eurasian Patent Organization200901313► Subscribe
HungaryE028712► Subscribe
HungaryE031334► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Pharmacyclics Inc Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2016 00056Denmark► SubscribePRODUCT NAME: IBRUTINIB, ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; REG. NO/DATE: EU/1/14/945 C(2016)3293 20160530
2015017,C2201840Lithuania► SubscribePRODUCT NAME: IBRUTINIBAS ARBA JO FARMACINIU POZIURIU PRIIMTINA DRUSKA; REGISTRATION NO/DATE: EU/1/14/945 20141021
90021-0Sweden► SubscribePRODUCT NAME: IBRUTINIB ELLER ETT FARMACEUTISKT GODTAGBART SALT DAERAV; REG. NO/DATE: EU/1/14/945 20141023
15/020Ireland► SubscribePRODUCT NAME: IBRUTINIB, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REGISTRATION NO/DATE: EU/1/14/945 20141021
00728Netherlands► SubscribePRODUCT NAME: IBRUTINIB OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT ERVAN; REGISTRATION NO/DATE: EU/1/14/945 20141021
0150014 00145Estonia► SubscribePRODUCT NAME: IBRUTINIIB;REG NO/DATE: EU/1/14/945 23.10.2014
0728Netherlands► SubscribeDETAILS ASSIGNMENT: VERANDERING VAN EIGENAAR(S), SAMENVOEGEN
2017009Lithuania► SubscribePRODUCT NAME: IBRUTINIBAS ARBA JO FARMACINIU POZIURIU PRIIMTINA DRUSKA; REGISTRATION NO/DATE: EU/1/14/945 C(2015)4704 20170703
2017 00012Denmark► SubscribePRODUCT NAME: IBRUTINIB, ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; REG. NO/DATE: EU/1/14/945 C(2015)4704 20150707
2016034Lithuania► SubscribePRODUCT NAME: IBRUTINIBAS ARBA FARMACISKAI PRIIMTINA JO DRUSKA; REGISTRATION NO/DATE: EU/1/14/945 C(2016)3293 20160526
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Chubb
Farmers Insurance
Argus Health
Mallinckrodt
Harvard Business School
Fuji
Express Scripts
Teva
Merck
Novartis

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot